For the Inventor, By the Inventor

Enter assignee name

Kirkland, Canada

Merck Frosst Canada, Inc.

Calculating rank

USPTO Granted Patents = 212

% Expired Patents = 6.1

CIPO Patents = 5

EPO Patents = 7

Forward Citations = 4,185

Loading Chart...

Loading Chart...

182 inventors (with patents filed for the assignee):

Robert N Young (35 out of 65 patents)

Joshua Rokach (35 out of 60 patents)

Yvan Guindon (32 out of 46 patents)

4. Yves Girard (32 out of 48 patents)

5. John W Gillard (28 out of 31 patents)

6. Rejean Fortin (27 out of 36 patents)

7. Serge Leger (23 out of 31 patents)

8. Cheuk K Lau (23 out of 41 patents)

9. Zhaoyin Wang (22 out of 50 patents)

10. Petpiboon Prasit (22 out of 28 patents)

11. Michel Therien (21 out of 37 patents)

12. Yves Ducharme (20 out of 29 patents)

13. Yves Leblanc (18 out of 40 patents)

14. John Howard Hutchinson (18 out of 112 patents)

15. Richard Frenette (18 out of 27 patents)

Core Competencies:

Cox-2 Inhibitors

EP4 Receptor Ligands

Protease Inhibitors

PDE4 Inhibitors

Cyclooxygenase-2

Leukotriene Antagonists

Pharmaceutical Compounds

Aryl Compounds

Indole Derivatives

Pyridine Analogues

Antagonists

Biaryl Compounds

212 patents: Sort by Forward Citations

1. 8969394 - Thiophenecarboxamide derivatives as EP4 receptor ligands (2015-03-03),

2. 8772336 - Cathepsin cysteine protease inhibitors (2014-07-08),

3. RE42562 - EPreceptor agonist, compositions and methods thereof (2011-07-18),

4. 7968578 - Indole amide derivatives as EP4 receptor antagonists (2011-06-28),

5. 7943649 - 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors (2011-05-17),

6. 7928091 - Cathepsin cysteine protease inhibitors (2011-04-19),

7. 7799787 - Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2010-09-21),

8. 7754745 - Azacyclopentane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2010-07-13),

9. 7705035 - Indoline amide derivatives as EP4 receptor ligands (2010-04-27),

10. 7696222 - Indole derivatives as CRTH2 receptor antagonists (2010-04-13),

11. 7629467 - Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use (2009-12-08),

12. 7618994 - Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment (2009-11-17),

13. 7618979 - Pyridopyrrolizine and pyridoindolizine derivatives (2009-11-17),

14. 7582633 - Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase (2009-09-01),

15. 7553973 - Pharmaceutical compounds (2009-06-30),

Company Overview

Merck Frosst Canada, Inc., based in Kirkland, Canada, specializes in the development and manufacturing of pharmaceutical compounds, particularly focusing on Cox-2 inhibitors and related technologies. The company is engaged in advanced research on EP4 receptor ligands, protease inhibitors, PDE4 inhibitors, and leukotriene antagonists, contributing to innovative therapeutic solutions. With a strong emphasis on aryl compounds, Merck Frosst plays a significant role in enhancing treatment options within the pharmaceutical industry.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

212 Patents

#1 in Kirkland

#51 in Canada

#4,014 in the World

Kirkland, Canada

Merck Frosst Canada, Inc.

Forward Citations = 4,185

182 inventors:

Robert N Young (35 out of 65 patents)

Joshua Rokach (35 out of 60 patents)

Yvan Guindon (32 out of 46 patents)

4. Yves Girard (32 out of 48 patents)

5. John W Gillard (28 out of 31 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Merck Frosst Canada, Inc.. Retrieved from https://idiyas.com/company/merck-frosst-canada

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…